COMMUNIQUÉS West-GlobeNewswire

NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note
30/01/2024
DURHAM, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced it [...]
Accompany Health Launches to Care for Low-Income Patients with Complex Needs
30/01/2024
New Company Raises $56 Million Series A Funding Round BETHESDA, Md., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Accompany Health , a primary, behavioral, and social care provider for low-income patients with complex needs, [...]
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
30/01/2024
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]
Immutep Quarterly Activities Report Q2 FY24
30/01/2024
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS ≥1%) [...]
Tome Biosciences Appoints Industry Veteran Daniel Curran, MD, to its Board of Directors
30/01/2024
WATERTOWN, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran was [...]
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
30/01/2024
PLEASANTON, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today that the United States Food and Drug [...]
iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member
30/01/2024
Mr. Doyle offers extensive experience in AI enabled healthcare platforms and global business strategy. NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI- [...]
Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS
30/01/2024
Over 2,100 registrants with attendees from 92 countries Average daily attendance of 574 32 oral presentations delivered across four consecutive days 69 scientific posters featuring optical genome mapping (OGM) on view [...]
ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics
30/01/2024
Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason [...]
Spectral Medical Provides January Tigris Trial Update
30/01/2024
85 patients enrolled TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock [...]
Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil
30/01/2024
The first THC containing pharmaceutical preparations produced in Brazil approved by the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria, “ANVISA”) TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- [...]
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
30/01/2024
All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company's cash position BRAINTREE, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Microbot [...]
VPR Brands Triumphs Again in PTAB Ruling, Upholding Key Electronic Cigarette Patent
30/01/2024
The Company's Robust Patent and Trademark Portfolio and Innovation in Vaping Technologies Make it a Key Player in Product Development for Vaping Technologies, Catering to Both Nicotine and Cannabis Markets FORT [...]
Kraig Biocraft Laboratories Signs Pivotal MOU in Vietnam's Silk Production Capital
30/01/2024
ANN ARBOR, Mich., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), signs key Memorandum of Understanding (MOU) with the Vietnam Sericulture Association (VSA) and the Lam [...]
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
30/01/2024
Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc [...]
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
30/01/2024
GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM ) , a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage [...]
As Omicron subvariants continue their worldwide transmission, CoVaRR-Net awarded another year of funding
30/01/2024
OTTAWA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- COVID-19, although no longer considered by the World Health Organization as a public-health emergency of international concern, remains a threat in Canada and worldwide. [...]
Alors que la transmission de sous-variants d'Omicron se poursuit dans le monde, une nouvelle année de financement est octroyée au réseau CoVaRR-Net
30/01/2024
OTTAWA, 30 janv. 2024 (GLOBE NEWSWIRE) -- La COVID-19, bien qu'elle ne soit plus considérée par l'Organisation mondiale de la Santé comme une urgence de santé publique de portée internationale, demeure une menace au [...]
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
30/01/2024
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of patients remain on [...]

Pages